Noonan Syndrome

Mouse model of leukemia yields therapeutic implications for rare cancer

Published in Cancer Weekly, March 8th, 2005

A new study provides direct evidence that mutations associated with certain forms of leukemia transform blood cells into abnormal cancer cells.

The research, published in Cancer Cell, examines the molecular signals involved in this transformation and suggests new therapeutic approaches for a rare lethal form of childhood leukemia.

The protein Shp2 is required for normal growth factor and cytokine signaling. Mutations in Shp2 cause Noonan syndrome (NS), which is associated with an increased risk of juvenile myelomonocytic leukemia (JMML), and Shp2 mutations have been associated with sporadic JMML as well as other leukemias. Dr. M. Golam Mohi, a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry